Next Article in Journal
Next Article in Special Issue
Previous Article in Journal
A comment was published on 10 June 2010, see Pharmaceuticals 2010, 3(6), 1887-1891.

Pharmaceuticals 2010, 3(1), 146-157; doi:10.3390/ph3010146
Review

Impact of Glycosylation on Effector Functions of Therapeutic IgG

1,2,3,4
 and 1,2,3,*
Received: 15 December 2009; in revised form: 30 December 2009 / Accepted: 8 January 2010 / Published: 12 January 2010
(This article belongs to the Special Issue Monoclonal Antibody)
View Full-Text   |   Download PDF [1675 KB, uploaded 13 January 2010]   |   Browse Figure
Abstract: Human IgG has only one conserved glycosylation site located in the Cγ2 domain of the Fc region that accounts for the presence of two sugar moieties per IgG. These IgG sugar cores play a critical role in a number of IgG effector functions. In the present review, we describe the main characteristics of IgG Fc glycosylation and some abnormalities of serum IgG glycosylation. We also discuss how glycosylation impacts on monoclonal antibodies (mAbs) and IVIg effector functions and how these molecules can be engineered. Several therapeutic antibodies have now been engineered to be no- or low-fucose antibodies and are currently tested in clinical trials. They exhibit an increased binding to activating FcγRIIIA and trigger a strong antibody-dependent cell cytotoxicity (ADCC) as compared to their highly-fucosylated counterparts. They represent a new generation of therapeutic antibodies that are likely to show a better clinical efficacy in patients, notably in cancer patients where cytotoxic antibodies are needed.
Keywords: antibody; Fc receptor; glycosylation; IgG antibody; Fc receptor; glycosylation; IgG
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Abès, R.; Teillaud, J.-L. Impact of Glycosylation on Effector Functions of Therapeutic IgG. Pharmaceuticals 2010, 3, 146-157.

AMA Style

Abès R, Teillaud J-L. Impact of Glycosylation on Effector Functions of Therapeutic IgG. Pharmaceuticals. 2010; 3(1):146-157.

Chicago/Turabian Style

Abès, Riad; Teillaud, Jean-Luc. 2010. "Impact of Glycosylation on Effector Functions of Therapeutic IgG." Pharmaceuticals 3, no. 1: 146-157.



Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert